4.7 Article

The 10 x '20 Initiative: Pursuing a Global Commitment to Develop 10 New Antibacterial Drugs by 2020

期刊

CLINICAL INFECTIOUS DISEASES
卷 50, 期 8, 页码 1081-1083

出版社

OXFORD UNIV PRESS INC
DOI: 10.1086/652237

关键词

-

资金

  1. Cubist
  2. Johnson Johnson
  3. Wyeth Pharmaceuticals
  4. Bayer Pharmaceuticals
  5. Cerexa
  6. Nabriva
  7. Trius
  8. Pfizer
  9. Merck
  10. Astellas
  11. Gilead
  12. Enzon
  13. Novartis

向作者/读者索取更多资源

The time has come for a global commitment to develop new antibacterial drugs. Current data document the impending disaster due to the confluence of decreasing investment in antibacterial drug research and development concomitant with the documented rapid increase in the level of resistance to currently licensed drugs. Despite the good faith efforts of many individuals, professional societies, and governmental agencies, the looming crisis has only worsened over the past decade.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据